EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR -mutant non-small-cell lung cancer (NSCLC).
Resource Type
Article
Authors
Nassar, Amin ; Adib, Elio ; Feng, Jamie ; Aredo, Jacqueline V. ; Parikh, Kaushal ; Harris, Jeremy Phillip ; Velazquez Manana, Ana I. ; Ragavan, Meera Vimala ; Lin, Jessica Jiyeong ; Piotrowska, Zofia ; Fitzgerald, Bailey Gleason ; Grohé, Christian ; Sankar, Kamya ; Neal, Joel W. ; Wakelee, Heather A. ; Shepherd, Frances A. ; Herbst, Roy S. ; Naqash, Abdul Rafeh ; Goldberg, Sarah B. ; Kim, So Yeon
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p8567-8567, 1p
Subject
Language
ISSN
0732183X